Back to Provider Blog

Hormonal Replacement after Breast Cancer: What’s New?

3 min read

Hormone replacement therapy (HRT) in menopause for women with a history of breast cancer remains one of the most complex and debated topics in gynecological endocrinology. For a long time, an extremely conservative approach prevailed, focused on the fear of recurrence. However, new evidence and guidelines now allow for a more personalized and balanced evaluation.

Hormone replacement therapy (HRT) in menopause for women with a history of breast cancer remains one of the most complex and discussed topics in gynecological endocrinology. For a long time, an extremely conservative approach prevailed, focused on the fear of recurrence. However, new evidence and guidelines now allow for a more personalized and balanced evaluation.

Understanding the complexity: the role of tumor biology

Not all breast cancers respond the same way to hormones. Therefore, it is essential to understand the histology and molecular profile of the tumor:

Tumor subtype Hormonal receptors Implication for HRT
Invasive ductal carcinoma ER+ ER+/PR+ Contraindicates systemic HRT
Pure HER2+ carcinoma No hormonal expression Case-by-case evaluation
Triple-negative (ER-, PR-, HER2-) Absence of receptors Greater openness to discuss HRT
Curable in situ carcinoma (DCIS/LCIS) Dependent on subtype May be considered

What do the main evidences say?

  • The CGHFBC meta-analysis published in The Lancet (2019) noted an increased risk of recurrence with the continuous use of combined HRT in women with ER+ cancer.
  • Isolated estrogen demonstrated much lower risk, primarily in women who have undergone hysterectomy.
  • An integrative review published in 2025 (Acervo Saúde) showed that the duration and type of hormone used directly influence this risk.

New guidelines: more individualization

The NICE (2024) and BMS (2024) guidelines propose a more flexible approach:

  • Systemic HRT remains contraindicated in active or recent ER+ breast cancers.
  • It may be discussed in cases of triple-negative or HER2+ cancer, cured many years ago, always with the approval of the oncologist and specialized team.

Vaginal estrogen: a safe option?

  • According to NICE and BMS, low-dose vaginal estrogen does not increase the risk of recurrence in women with ER+ breast cancer.
  • A study presented at ASCO 2025 showed that women over 65 who used vaginal cream showed reduced mortality.
  • They may be indicated for urogenital symptoms such as vaginal dryness, dyspareunia, and recurrent urinary infections, always with multidisciplinary follow-up.

Practical tips for clinical practice

  • Active or recent ER+ breast cancer: formal contraindication for systemic HRT.
  • Triple-negative, pure HER2+, or cured DCIS: may allow individualized evaluation.
  • Local low-dose vaginal estrogen: safe even in ER+, with oncologist approval.
  • The therapeutic decision must be shared and multidisciplinary, considering risks, benefits, and the patient’s quality of life.

References:

  • NICE. Menopause: identification and management (NG23). 2024.
  • British Menopause Society (BMS). Consensus Statement, 2024.
  • The Lancet. Type and timing of menopausal hormone therapy and breast cancer risk. 2019.
  • Acervo Saúde. Hormonal therapy in menopause and breast cancer: integrative review. 2025.
  • Reuters Health. Older breast cancer patients using estrogen cream live longer. 2025.
  • The Times. Menopausal cancer survivors offered HRT under new guidance. 2025.

Article written by Dr. Francisco Tostes, Scientific Director at Renewal.

Dr. Francisco Tostes

Scientific Director, Renewal

#hormone replacement #breast cancer #news

Privacy Officer

Contact us

Use this form for privacy questions or to exercise your rights under PIPEDA. Our team will follow up by email.

We promise not to use your contact information to send any type of spam.